A partially-blinded, randomized, placebo and active controlled, ascending single-dose crossover phase I study to explore the safety, tolerability, pharmacokinetic and pharmacodynamic effects of PTH134 formulated with different concentrations of 5-CNAC in healthy postmenopausal women

Trial Profile

A partially-blinded, randomized, placebo and active controlled, ascending single-dose crossover phase I study to explore the safety, tolerability, pharmacokinetic and pharmacodynamic effects of PTH134 formulated with different concentrations of 5-CNAC in healthy postmenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2009

At a glance

  • Drugs Teriparatide; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 18 Oct 2009 Results reported at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
    • 10 Dec 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 30 Jun 2008 Results are expected by the end of 2008, according to an Emisphere media release (9090628).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top